The susceptibility of baboons to the novel immunosuppressant, FTY720

Simple item page
dc.contributor.advisorQuesniaux, Valerieen_ZA
dc.contributor.authorSemple, P Len_ZA
dc.date.accessioned2014-07-29T09:10:28Z
dc.date.available2014-07-29T09:10:28Z
dc.date.issued2000en_ZA
dc.descriptionBibliography: leaves 109-118.
dc.description.abstractSince there is a major scarcity of donor organs world-wide, the experimental search for human organs has focused on two alternatives; mechanical devices and cross-species transplants. The use of mechanical devices as substitute organs is understandably limited due to complications from trying to duplicate the function of complex organs such as the liver. This has resulted in a renewed interest in xenotransplantation. Organs from non-human primates would arguably be the organs of choice but ethical consideration prevents this. The transplantation of organs from pigs or sheep to humans i.e. xenotransplants, results in hyperacute rejection. The development of immunosuppressive agents such as Cyc1osporine A and Tacrolimus have significantly improved the survival of organ transplants. However, although there is a good 1-5 year survival, the recurrent problem of chronic rejection still remains, and unresponsiveness to allografts has never been induced by these immunosuppressive agents. More importantly, the presence of adverse side effects including immunological complications and drug toxicity e.g. nephrotoxicity, remains a serious problem. Since the drugs currently available for allotransplantation preferably target T -cells, and are therefore unlikely to be sufficient for xenotransplantation where there is a strong B-cell driven response, there is a need for new immunosuppressive agents. FTY720 (2 amino-2-(2-[ 4-octylphenyl] ethyl)-1,3-propanediol hydrochloride), a novel, immunosuppressive drug active in rodent and dog transplantation models, has shown no toxic side effects in pre-clinical studies although no long-term patient studies exist.en_ZA
dc.identifier.apacitationSemple, P. L. (2000). <i>The susceptibility of baboons to the novel immunosuppressant, FTY720</i>. (Thesis). University of Cape Town ,Faculty of Health Sciences ,Department of Medicine. Retrieved from http://hdl.handle.net/11427/3463en_ZA
dc.identifier.chicagocitationSemple, P L. <i>"The susceptibility of baboons to the novel immunosuppressant, FTY720."</i> Thesis., University of Cape Town ,Faculty of Health Sciences ,Department of Medicine, 2000. http://hdl.handle.net/11427/3463en_ZA
dc.identifier.citationSemple, P. 2000. The susceptibility of baboons to the novel immunosuppressant, FTY720. University of Cape Town.en_ZA
dc.identifier.ris TY - Thesis / Dissertation AU - Semple, P L AB - Since there is a major scarcity of donor organs world-wide, the experimental search for human organs has focused on two alternatives; mechanical devices and cross-species transplants. The use of mechanical devices as substitute organs is understandably limited due to complications from trying to duplicate the function of complex organs such as the liver. This has resulted in a renewed interest in xenotransplantation. Organs from non-human primates would arguably be the organs of choice but ethical consideration prevents this. The transplantation of organs from pigs or sheep to humans i.e. xenotransplants, results in hyperacute rejection. The development of immunosuppressive agents such as Cyc1osporine A and Tacrolimus have significantly improved the survival of organ transplants. However, although there is a good 1-5 year survival, the recurrent problem of chronic rejection still remains, and unresponsiveness to allografts has never been induced by these immunosuppressive agents. More importantly, the presence of adverse side effects including immunological complications and drug toxicity e.g. nephrotoxicity, remains a serious problem. Since the drugs currently available for allotransplantation preferably target T -cells, and are therefore unlikely to be sufficient for xenotransplantation where there is a strong B-cell driven response, there is a need for new immunosuppressive agents. FTY720 (2 amino-2-(2-[ 4-octylphenyl] ethyl)-1,3-propanediol hydrochloride), a novel, immunosuppressive drug active in rodent and dog transplantation models, has shown no toxic side effects in pre-clinical studies although no long-term patient studies exist. DA - 2000 DB - OpenUCT DP - University of Cape Town LK - https://open.uct.ac.za PB - University of Cape Town PY - 2000 T1 - The susceptibility of baboons to the novel immunosuppressant, FTY720 TI - The susceptibility of baboons to the novel immunosuppressant, FTY720 UR - http://hdl.handle.net/11427/3463 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/3463
dc.identifier.vancouvercitationSemple PL. The susceptibility of baboons to the novel immunosuppressant, FTY720. [Thesis]. University of Cape Town ,Faculty of Health Sciences ,Department of Medicine, 2000 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/3463en_ZA
dc.language.isoengen_ZA
dc.publisher.departmentDepartment of Medicineen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.subject.otherMedicineen_ZA
dc.titleThe susceptibility of baboons to the novel immunosuppressant, FTY720en_ZA
dc.typeMaster Thesis
dc.type.qualificationlevelMasters
dc.type.qualificationnameMScen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceThesisen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
thesis_hsf_2000_semple_pl (11).pdf
Size:
4.25 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Masters